TMCnet News
Schrödinger Appoints Veteran Biotech Industry Leader Dr. Rosana Kapeller to Board of DirectorsSchrödinger, a privately held company revolutionizing drug discovery and materials design through advanced molecular simulations, today announced the appointment of veteran biotech leader Rosana Kapeller, M.D., Ph.D., to its board of directors. "I am delighted and honored to join Schrödinger during such a pivotal time in the company's growth," said Dr. Kapeller. "I look forward to working with the team to help leverage their computational platform to expand their software business and build an exciting pipeline of novel therapeutics." Dr. Kapeller brings over two decades of biotech leadership experience and is deeply familiar with Schrödinger's platform, having spent eight years in an executive role at Nimbus Therapeutics, a computation-driven drug discovery company co-founded by Atlas Venture and Schrödinger. As founding chief scientific officer of Nimbus, Dr. Kapeller led an interdisciplinary team that advanced multiple promising programs by applying Schrödinger's computational technologies to the desin and development of novel therapeutics. Dr. Kapeller currently serves as the first entrepreneur-in-residence focused on life sciences at GV (formerly Google (News - Alert) Ventures). GV invested in Schrödinger as part of an $85 million funding round announced earlier this month. At GV, Dr. Kapeller focuses on the intersection of therapeutics and machine learning. Prior to her time at Nimbus, Dr. Kapeller worked as vice president of research at Aileron Therapeutics. She started her career as a scientist at Millennium Pharmaceuticals, where she advanced through positions of increasing responsibility to director. Dr. Kapeller has served as an adviser to Atlas Venture and a consultant to Third Rock Ventures and sits on the board of Cedilla Therapeutics. She holds a doctorate degree in molecular and cellular physiology from Tufts University and a medical degree from Universidade do Estado do Rio de Janeiro in Brazil. "Rosana is an invaluable addition to our board, given her extensive background and deep expertise in drug discovery," said Ramy Farid, Ph.D., Schrödinger's CEO. "We are excited to work with her as we continue to invest in our computational platform, grow our software business, and progress our drug discovery programs."
About Schrödinger
View source version on businesswire.com: https://www.businesswire.com/news/home/20190123005077/en/ |